(Q24247171)

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

Severe Community-acquired Pneumonia: Epidemiology and Prognostic Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Comparative study of azithromycin and amoxicillin/clavulanic acid in the treatment of lower respiratory tract infections.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

A randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Prospective study of the aetiology and outcome of pneumonia in the community

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. The British Thoracic Society Research Committee and The Public Health Laboratory Service

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Comparison of spiramycin and doxycycline in the treatment of lower respiratory infections in general practice

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Sparfloxacin as alternative treatment to standard therapy for community-acquired bacteremic pneumococcal pneumonia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Comparative radiographic features of community acquired Legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia, and psittacosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Ofloxacin once daily versus twice daily in community-acquired pneumonia and acute exacerbation of chronic bronchitis. A randomized multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Community-acquired pneumonia: the annual cost to the National Health Service in the UK.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients. A multicenter, double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021

Oral empiric treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. The Scandinavian Sparfloxacin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002109.PUB2

7 January 2021